ATE480543T1 - Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase - Google Patents

Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase

Info

Publication number
ATE480543T1
ATE480543T1 AT07732669T AT07732669T ATE480543T1 AT E480543 T1 ATE480543 T1 AT E480543T1 AT 07732669 T AT07732669 T AT 07732669T AT 07732669 T AT07732669 T AT 07732669T AT E480543 T1 ATE480543 T1 AT E480543T1
Authority
AT
Austria
Prior art keywords
inhibitors
neutrophil elastase
human neutrophil
tetrahydropyrrolopyrimidiindione
hne
Prior art date
Application number
AT07732669T
Other languages
English (en)
Inventor
Nicholas Ray
Harry Finch
Christine Edwards
Elizabeth O'connor
Original Assignee
Pulmagen Therapeutics Inflamma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608844A external-priority patent/GB0608844D0/en
Priority claimed from GB0612544A external-priority patent/GB0612544D0/en
Application filed by Pulmagen Therapeutics Inflamma filed Critical Pulmagen Therapeutics Inflamma
Application granted granted Critical
Publication of ATE480543T1 publication Critical patent/ATE480543T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT07732669T 2006-05-04 2007-05-03 Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase ATE480543T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0608844A GB0608844D0 (en) 2006-05-04 2006-05-04 Enzyme inhibitors
GB0612544A GB0612544D0 (en) 2006-06-23 2006-06-23 Enzyme inhibitors
PCT/GB2007/001638 WO2007129060A1 (en) 2006-05-04 2007-05-03 Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors

Publications (1)

Publication Number Publication Date
ATE480543T1 true ATE480543T1 (de) 2010-09-15

Family

ID=38226415

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07732669T ATE480543T1 (de) 2006-05-04 2007-05-03 Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase

Country Status (20)

Country Link
US (1) US8957082B2 (de)
EP (1) EP2024367B1 (de)
JP (1) JP4999920B2 (de)
AT (1) ATE480543T1 (de)
AU (1) AU2007246889B2 (de)
BR (1) BRPI0711169A2 (de)
CA (1) CA2657956C (de)
CY (1) CY1111437T1 (de)
DE (1) DE602007009095D1 (de)
DK (1) DK2024367T3 (de)
EA (1) EA018061B1 (de)
IL (1) IL194843A (de)
MX (1) MX2008013996A (de)
NO (1) NO20084502L (de)
NZ (1) NZ572250A (de)
PL (1) PL2024367T3 (de)
PT (1) PT2024367E (de)
SI (1) SI2024367T1 (de)
WO (1) WO2007129060A1 (de)
ZA (1) ZA200809250B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
DE602007009095D1 (de) 2006-05-04 2010-10-21 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
WO2009013444A1 (en) * 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
EP2064184A1 (de) * 2006-09-04 2009-06-03 AstraZeneca AB Als inhibitoren der neutrophilen-elastase geeignete multimere heterocyclische verbindung
EP2217591A4 (de) 2007-11-06 2011-10-26 Astrazeneca Ab 2-pyrazinonderivate und ihre verwendung als inhibitoren neutrophiler elastase
WO2009060158A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
WO2009060206A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
GB0721866D0 (en) * 2007-11-07 2007-12-19 Argenta Discovery Ltd Pharmaceutical compounds having dual activities
DE102008052013A1 (de) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
CN101903356B (zh) 2007-12-20 2013-05-22 拜耳知识产权有限责任公司 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
GB0817429D0 (en) * 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
CA2751054A1 (en) 2009-01-30 2010-08-05 Chiesi Farmaceutici S.P.A. Dimeric pyrrolopyrimidinedione and its use in therapy of respiratory diseases
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AU2010302420B2 (en) 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
GB201004178D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004179D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
CA2848557A1 (en) * 2011-09-14 2013-03-21 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN105873933A (zh) 2013-12-16 2016-08-17 奇斯药制品公司 作为人中性白细胞弹性蛋白酶抑制剂的四氢三唑并嘧啶衍生物
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9487528B2 (en) 2014-06-09 2016-11-08 Chiesi Farmaceutici S.P.A. Compounds
US9440930B2 (en) * 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) * 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) * 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
KR20170129191A (ko) 2015-03-18 2017-11-24 바이엘 파마 악티엔게젤샤프트 (4s)-4-[4-사이아노-2-(메틸설폰일)페닐]-3,6-다이메틸-2-옥소-1-[3-(트라이플루오로메틸)페닐]-1,2,3,4-테트라하이드로 피리미딘-5-카보나이트릴의 생성 방법
JP7672641B2 (ja) 2019-09-17 2025-05-08 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
IL297211B2 (en) 2020-04-16 2025-12-01 Mereo Biopharma 4 Ltd Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
WO2004024701A1 (en) * 2002-09-10 2004-03-25 Bayer Healthcare Ag Heterocyclic derivatives
EP1546113B1 (de) 2002-09-10 2013-05-01 Bayer Intellectual Property GmbH Pyrimidinonderivate als therapeutische mittel gegen aktute und chronische entzündliche, ischämische und verändernde prozesse
GB0502258D0 (en) * 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
GB0520743D0 (en) * 2005-10-12 2005-11-23 Argenta Discovery Ltd Compounds and their use
DE602007009095D1 (de) 2006-05-04 2010-10-21 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase

Also Published As

Publication number Publication date
BRPI0711169A2 (pt) 2011-08-23
PT2024367E (pt) 2010-12-03
SI2024367T1 (sl) 2011-04-29
MX2008013996A (es) 2009-01-14
JP2009535389A (ja) 2009-10-01
EP2024367B1 (de) 2010-09-08
ZA200809250B (en) 2010-02-24
EA200870391A1 (ru) 2009-06-30
JP4999920B2 (ja) 2012-08-15
US8957082B2 (en) 2015-02-17
CA2657956A1 (en) 2007-11-15
EA018061B1 (ru) 2013-05-30
HK1130794A1 (en) 2010-01-08
AU2007246889A1 (en) 2007-11-15
WO2007129060A1 (en) 2007-11-15
PL2024367T3 (pl) 2011-05-31
DK2024367T3 (da) 2011-01-03
IL194843A (en) 2014-04-30
AU2007246889B2 (en) 2011-03-10
CA2657956C (en) 2015-01-06
CY1111437T1 (el) 2015-08-05
NO20084502L (no) 2008-11-26
US20120202826A1 (en) 2012-08-09
DE602007009095D1 (de) 2010-10-21
IL194843A0 (en) 2009-08-03
EP2024367A1 (de) 2009-02-18
NZ572250A (en) 2011-10-28

Similar Documents

Publication Publication Date Title
ATE480543T1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
EA200802213A1 (ru) Способы лечения заболеваний крови
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
EA201170521A1 (ru) Новые соединения
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
DE602006016150D1 (de) Vorbeugung von krankheiten bei kaiserschnitt-babies
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
DE602005022113D1 (de) Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE494926T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
ATE523199T1 (de) Pyridazinverbindungen und verfahren
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2024367

Country of ref document: EP